CV6 Therapeutics Announces Initiation of Patient Dosing in Phase 1a Clinical Trial Evaluating the Investigational First-In-Class, Specific dUTPase Inhibitor CV6-168
Belfast, UK, 15 August 2024 –CV6 Therapeutics (NI) Ltd. (“CV6”), a clinical-stage pharmaceutical company dedicated to improving the lives of patients with cancer and inflammatory diseases by developing novel, first-in-class, small molecules targeting Uracil-DNA metabolism, today announced the successful dosing of the second patient in its Phase 1a study evaluating CV6-168 + infusional 5-fluorouracil (5-FU) in cancer patients.
